National clinical guidelines don’t mention screening cancer patients for DPYD gene variants, but hospital pharmacy leaders are forging ahead with the patient safety practice, the American Society of ...

Genomic medicine leverages an individual’s genetic information to guide healthcare decisions, with drug-gene testing (also known as pharmacogenomics, or PGx) being a key application that personalizes ...

Pretreatment DPYD testing is standard of care in several National Cancer Institute–designated Comprehensive Cancer Centers, much of Canada, and virtually all of Europe. All medical oncologists in the ...

A prospective trial of gastrointestinal cancer patients showed the feasibility of preemptive genetic testing for DPYD/UGT1A1 variants associated with increased chemotherapy toxicity. Genotype-guided ...

A man in his early 70s died after adjuvant chemotherapy due to fulminant gastrointestinal toxicity and bowel ischaemia linked to an undetected dihydropyrimidine dehydrogenase (DPYD) deficiency, ...

Please provide your email address to receive an email when new articles are posted on . Genetic testing can be accomplished for most patients with gastrointestinal cancer prior to starting ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. John Meehan and his wife, Mary Ellen, moved to Charlotte ...

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced its new DPYD algorithm as its most recent addition to its growing collection of predictive ...

Almost all of us have been touched by cancer at some point in our lives. If we haven’t had it, chances are we know a loved one or a friend who has. When someone dies from cancer, families go through ...

In the 21st century, oncology has achieved extraordinary progress. We can decode a tumor’s genome, tailor therapies to molecular targets, and extend survival through precision treatments. Yet, despite ...

- Company Revamps Pharmacogenomics Go-To-Market Strategy, Targets Validated PGx Assay Towards Specific Use Cases - STONY BROOK, NY / ACCESS Newswire / April 1, 2025 / Applied DNA Sciences, Inc.

STONY BROOK, NY / ACCESS Newswire / April 1, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that Applied DNA ...